osimertinib
astrazeneca
['adaura', 'nsclc', 'lcsm,(-blcsm)', 'sclc', 'osimertinib', 'aura ,(-laura)']
so, it is out! adaura demonstrated a clear benefit of osimertinib in egfr+ resected nsclc. no benefit in ib or ii patients. we still want to see how many patients did receive osi in the placebo arm, but, as for now, it is clearly a soc. #asco23 #lcsm 
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.